Experiments performed using a bleomycin-instilled mouse model of pulmonary fibrosis showed that salvianolic acid B, the major ingredient of Salviae miltiorrhiza, had strong anti-inflammatory and anti-fibrotic effects through its inhibition of inflammatory cell infiltration, alveolar structure disruption, and collagen deposition. [Sci Rep]
Full Article

Male Wistar rats and the rat alveolar epithelial cell line, RLE-6TN, were exposed to normal air or different concentrations of cigarette smoke extract (CSE). Then phospholipid transfer protein siRNA was transfected into cells and an inhibitor of transforming growth factor-β1 was administered prior to CSE exposure. [Eur J Pharmacol]
Abstract

The authors studied the role of human serum and glucocorticoid-inducible kinase (SGK1) in the regulation of fatty acids uptake in cancer cells exposed to acute or chronic cycling hypoxia and explore its use as target for the radiosensitization of hypoxic cancer cells. [Radiat Oncol]
Full Article

The authors report a case of hereditary muco-epithelial dysplasia that presented with pulmonary fibrosis and emphysema on high-resolution computed tomography. This case illustrates a more generalizable concept of epithelial disintegrity in the development of fibrotic lung diseases, which is explored in greater detail in this review article. [Am J Physiol Lung Cell Mol Physiol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the pulmonary cell research field.

Pfizer Inc. announced encouraging new data from a Phase I/II study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. [Press release from Pfizer Inc. discussing research presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago]
Press Release

Merck announced findings from an initial proof-of-concept study of KEYTRUDA®, the company’s anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC. [Press release from Merck & Co., Inc. discussing research presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago]
Press Release

Xcovery announced that results from an expansion cohort in the ongoing Phase I/II clinical study of its investigational tyrosine kinase inhibitor, ensartinib, in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer were presented [Press release from Xcovery discussing research presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago]
Press Release

Boehringer Ingelheim will announce updated results from the Phase II part of the HM-EMSI-101 trial. [Press release from Boehringer Ingelheim GmbH discussing research presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago]
Press Release

Boehringer Ingelheim announced it has established a research collaboration with the Harvard Stem Cell Institute’s – Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis, chronic kidney disease and nonalcoholic steatohepatitis. [Boehringer Ingelheim GmbH]
Press Release

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology agents Opdivo and Yervoy to treat early- and advanced-stage lung cancer patients. [The University of Texas MD Anderson Cancer Center]
Press Release